A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Study Summary

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

Conditions

Diabetes Mellitus, Type 1

Interventions / Drugs

Insulin icodec Insulin glargine Insulin aspart

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment877 participants

Primary Completion—

Lead SponsorNovo Nordisk A/S

Data Retrieved2026-04-11 02:55:47.367073+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.